Brief: Tango Therapeutics Reports Fourth Quarter Results

Tango Therapeutics

27/03/2023 15:25

March 27 (Reuters) - Tango Therapeutics Inc  TNGX.O :
    * TANGO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS
    * AN UPDATE FROM ONGOING DOSE ESCALATION TRIAL FOR TNG908
FOCUSED
ON PROOF-OF-MECHANISM IS ON TRACK FOR Q2 OF 2023
    * IND FILING FOR TNG260 IS ON TRACK FOR FIRST HALF OF 2023
    * INITIATION OF PHASE 1/2 CLINICAL TRIAL FOR TNG462 IS ON
TRACK
FOR MID-2023
    * QTRLY LOSS PER SHARE $0.33
    * Q4 EARNINGS PER SHARE VIEW $-0.36 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX1WfkTW 
Further company coverage:  TNGX.O